[1]和新盈,王书文,李 宇,等.miR-25靶向作用FBXO33在肾透明细胞癌凋亡及预后的相关实验研究[J].现代检验医学杂志,2017,32(01):38-40,44.[doi:10.3969/j.issn.1671-7414.2017.01.011]
　HE Xin-ying,WANG Shu-wen,LI Yu,et al.Study on the Relationship of MiR-25 Targeting FBXO33 with Cell Apoptosis and Prognosis in Renal Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2017,32(01):38-40,44.[doi:10.3969/j.issn.1671-7414.2017.01.011]
点击复制

miR-25靶向作用FBXO33在肾透明细胞癌凋亡及预后的相关实验研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年01期
页码:
38-40,44
栏目:
论著
出版日期:
2017-01-25

文章信息/Info

Title:
Study on the Relationship of MiR-25 Targeting FBXO33 with Cell Apoptosis and Prognosis in Renal Cell Carcinoma
文章编号:
1671-7414(2017)01-038-04
作者:
和新盈1; 2; 王书文1; 李 宇3; 张冠军1
1.西安交通大学第一附属医院病理科,西安 710061;
2.西安医学院病理教研室,西安 710061;
3.陕西省人民医院放疗科,西安 710068
Author(s):
HE Xin-ying1; 2; WANG Shu-wen1; LI Yu3; ZHANG Guan-jun1
1.Department of Pathological Section,the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;
2.Pathological Staff Room,Xi'an Medical College,Xi'an 710061,China;
3.Department of Rediotherapy,Shaanxi Provincial People's Hosp
关键词:
miR-25;  FBXO33;  肾透明细胞癌;  细胞凋亡;  预后
分类号:
R737.11; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.01.011
文献标志码:
A
摘要:
目的 探索miR-25与FBXO33在肾透明细胞癌(renal cell carcinoma,RCC)中的相关性,并分析其与肾癌细胞凋亡及预后的关系。方法 从肿瘤基因图谱(the cancer genome atlas,TCGA)数据库中获取1998～2013年511例RCC芯片数据,Pearson检验分析miR-25和FBXO33表达的相关性; 检测miR-25对构建的FBXO33 3'UTR野生型、突变型及空白对照荧光素酶报告基因中荧光素表达的影响; CCK8法检测瞬转miR-25 mimic,siRNA及对照序列对RCC细胞活力的影响; 流式细胞术检测瞬转miR-25 mimic,siRNA及对照序列对RCC细胞凋亡的影响; TCGA数据库中筛选出miR-25与FBXO33表达负相关且具有随访的58例患者,分为miR-25低表达联合FBXO33高表达组(n=34)和miR-25高表达联合FBXO33低表达组(n=24)进行生存分析,采用Log-rank检验和Gehan-Breslow-Wilcoxon检验。结果 RCC组织中FBXO33与miR-25表达负相关(r=-0.161 1,Pearson检验)。与空白对照组相比,miR-25可降低野生型组RLU至80.2%±2.6%,差异具有统计学意义(t=6.539,P=0.006); 而突变序列组RLU为空白对照组的103.5%±8.4%,差异不具有统计学意义(t=0.041 3,P=0.968 4)。72 h细胞活力与空白对照组相比,miR-2 siRNA组提高32.7%±3.5%,差异具有统计学意义(P＜0.05); 而miR-25 mimic组降低23.3%±1.7%,差异具有统计学意义(P＜0.05)。mimic-miR-25-3p与其对照组比较,早期凋亡率降低(8.83±0.09 vs 12.83±0.14),差异具有统计学意义(t=42.17,P=0.005); 晚期凋亡率轻度升高(0.41±0.10 vs 0.33±0.15),差异无统计学意义(t=0.75,P=0.639); siRNA-miR-25-3p与其对照组比较,早期凋亡率升高(19.05±1.64 vs 13.68±0.78),差异具有统计学意义(t=5.12,P=0.006); 晚期凋亡率轻度降低(0.56±0.10 vs 0.62±0.08),差异无统计学意义(t=0.83,P=0.376)。miR-25低表达同时FBXO33高表达患者(n=34)与miR-25高表达而FBXO33低表达者(n=24)相比生存率更高,差异具有统计学意义(采用Log-rank检验P=0.025 2,采用Gehan-Breslow-Wilcoxon检验P=0.004 9)。结论 miR-25可抑制肾癌FBXO33,提高细胞活性,抑制凋亡而降低患者预后。
Abstract:
Objective To explore the correlation between miR-25 and FBXO33 in renal cell carcinoma(RCC),and to analyze the relationshipwith apoptosis and prognosis of renal cell carcinoma.Methods The 511 RCC chip results,from 1998 to 2013,were downloaded from the Cancer Genome Atlas(TCGA)database,and were analyzed for the correlation between miR-25 and FBXO33 by Pearson test.The expression of fluorescein were detected with the FBXO33 3'UTR wild-type,mutant and blank control luciferase reporter gene treated by miR-25.The viability of cells transient translated by the miR-25 mimic,siRNA and the controls were detected by CCK8 method.The apoptosis ofcells transient translated by the miR-25 mimic,siRNA and the controls were detected by flow cytometry.58 cases with follow-up data were screened from TCGAby expression of FBXO33 negative correlation miR-25.The survival was analyzedbetween low expression of miR-25 combined with FBXO33 high expression group(n=34)with high expression of miR-25 combined with FBXO33 low expression group(n=24),using Log-rank test and Gehan-Breslow-Wilcoxon test.Results FBXO33 was negatively correlated with miR-25 in RCC tissue(r=-0.161 1,Pearson test).Compared with the control group,miR-25 could reduce the RLU of wild type group to 80.2%±2.6%,the difference was statistically significant(t=6.539,P=0.006).The RLU of mutation group was103.5%±8.4% compared with that of blank control group,the difference was not statistically significant(t=0.041 3,P=0.968 4),compared with the blank group in 72h for the cell varibility,miR-25 siRNA group were elevated by 32.7%±3.5%,the difference was statistically significant(P＜0.05).The miR-25 mimic group were reduced by 23.3%±1.7%,the differencewas statistically significant(P＜0.05),and compared with the control group,the early apoptosis rate was decreased in mimic-miR-25-3p group(8.83±0.09 vs 12.83±0.14),while the difference was statistically significant(t=42.17,P=0.005).The late apoptosis rate was slightly escalated(0.41±0.10 vs 0.33±0.15),while the difference was not statistically significant(t=0.75,P=0.639).Compared with the control group,the early apoptosis rate was increased in siRNA-miR-25-3p group(19.05±1.64 vs 13.68±0.78),while the difference was statistically significant(t=5.12,P=0.006).But the late apoptosis rate was reduced(0.56±0.10 vs 0.62±0.08),while the difference was not statistically significant(t=0.83,P=0.376).The survival rate was higher in patients with low expression of miR-25 combined with high expression of FBXO33(n=34)than that of miR-25 high expression combined with low expression of FBXO33(n=24),the difference was statistically significant(Log-rank test P=0.025 2, Gehan-Breslow-Wilcoxon test P=0.004 9).Conclusion MiR-25 can inhibite FBXO33 in renal cell carcinoma,improve the cell activity,inhibit apoptosis and reduce the prognosis.

参考文献/References:

[1] Yu HS,Liu ZM,Yu XY,et al.Low-dose radiation induces antitumor effects and erythrocyte system hormesis[J].Asian Pacific Journal of CancerPrevention,2013,14(7):4121-4126.
[2] 梁 亮,张寅斌,马宇光,等.miR-25对三阴性乳腺癌细胞增殖和凋亡的影响及潜在机制[J].现代肿瘤医学,2016,24(20):3197-3201. Liang L,Zhang YB,Ma YG,et al.The effect of miR-25 on proliferation and apoptosis of triple negative breast cancer cells and the potential mechanism[J].Modern Oncology,2016,24(20):3197-3201.
[3] Xie CM,Wei W,Sun Y.Role of SKP1-CUL1-F-Box-Protein(SCF)E3 ubiquitin ligases in skin cancer[J].Journal of Genetics and Genomics,2013,40(3):97-106.
[4] Wei C,Liu J,Yu Z,et al.TALEN or Cas9-rapid,efficient and specific choices for genome modifications[J].Journal of Genetics and Genomics,2013,40(6):281-289.
[5] Mo Z,Zu X,Xie Z,et al.Antitumor effect of F-PBF(beta-TrCP)-inducedtargeted PTTG1 degradation in HeLa cells[J].Journal of Biotechnology,2009,139(1):6-11.
[6] Hudes GR,Carducci MA,Choueiri TK,et al.NCCN task force report:optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy[J].Journal of the National Comprehensive Cancer Network,2011,9(Suppl 1):S1-29.
[7] Faragalla H,Youssef YM,Scorilas A,et al.The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma[J].Journalof Molecular Diagnostics,2012,14(4):385-392.
[8] 唐海霞,王 成,路美玲,等.肾透明细胞癌患者血清miR-193a-3p水平增加及早期诊断价值[J].现代检验医学杂志,2015,30(3):43-45,49. Tang HX, Wang C, Lu ML,et al.Elevated serum miR-193a-3p levelin renal clear cell carcinoma and its early clinical value[J].Journal of Modern Laboratory Medicine,2015,30(3):43-45,49.
[9] 王 静,王 成,张春妮.血清miR-25和miR-100作为食管鳞状细胞癌诊断和预后标志物研究[J].现代检验医学杂志,2015,30(5):17-21. Wang J,Wang C,Zhang CN.Study on serum miR-25 and miR-100 as diagnostic and prognostic markers for esophageal squamous cell carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(5):17-21.
[10] Xie CM,Wei W,Sun Y.Role of SKP1-CUL1-F-Box-Protein(SCF)E3 ubiquitin ligases in skin cancer[J].Journal of Genetics and Genomics,2013,40(3):97-106.
[11] 田 钰,杨桂芳.FBXO31,Cyclin D1在胃癌中的表达及其临床意义[J].武汉大学学报(医学版),2014,05:707-709,732. Tian Y, Yang GF.The expression of FBXO31 and Cyclin D1 in gastric cancer and its clinical significance[J].Journal of Hubei Medical University(Medical Edition),2014,35(5):707-709,732.
[12] 张明慧,郭 炜,董稚明,等.食管鳞状细胞癌中FBXO32基因表达及其临床意义[J].临床与实验病理学杂志,2013,29(6):632-636. Zhang MH,Guo W,Dong ZM,et al.Expression of FBXO32 in esophageal squamous cell carcinoma and its clinical significance[J].Journal of Clinical and Experimental Pathology,2013,29(6):632-636.
[13] Wei CX,Liu JY,Yu ZS,et al.TALEN or Cas9-Rapid,Efficient and Specific Choices for Genome Modifications[J].Journal of Genetics and Genomics,2013,40(6):281-289.
[14] Mo Z,Zu X,Xie Z,et al.Antitumor effect of F-PBF(beta-TrCP)-induced targeted PTTG1 degradation in HeLa cells[J].Journal of Biotechnology,2009,139(1):6-11.

相似文献/References:

[1]王静,王成,张春妮.血清miR-25和miR-100作为食管鳞状细胞癌诊断和预后标志物研究[J].现代检验医学杂志,2015,30(05):17.[doi:10.3969/j.issn.1671-7414.2015.05.006]
　WANG Jing,WANG Cheng,ZHANG Chun-ni.Study on Serum miR-25 and miR-100 as Diagnostic and Prognostic Markers for Esophageal Squamous Cell Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(01):17.[doi:10.3969/j.issn.1671-7414.2015.05.006]

备注/Memo

备注/Memo:
基金项目:陕西省教育厅科学研究项目(12JK0699); 陕西省科学技术研究发展计划(2011JM4038)。
作者简介:和新盈(1972-),女,硕士研究生,副教授,主要研究方向:肿瘤分子病理,Tel:13991831377,E-mail:hxyxiyi@163.com。
通讯作者:张冠军,男,教授,主任医师,硕士生导师,主要研究方向:肾癌分子病理学研究及肿瘤病理诊断,E-mail:zgjdoc@163.com。
更新日期/Last Update: 2017-01-20